12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Resminostat: Additional Phase II data

Additional data from the open-label, German and Italian Phase II SHELTER trial in 45 patients with HCC refractory to Nexavar sorafenib showed that second-line treatment with resminostat in combination with Nexavar (n=26) produced a median OS of 8 months, while median OS for patients receiving resminostat alone was 4.1 months (n=19). 4SC said it believes the 8 month median OS in the combination arm is the highest median OS achieved in clinical studies of new therapies for second-line HCC. The result also appears to be an almost 3-month improvement...

Read the full 433 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >